Phase 3 Recruiting Academic/Other
This phase III trial compares the effect of dose-escalated radiation therapy to usual care in patients with locally advanced unresectable pancreatic ductal adenocarcinoma who have received an initial 4-6 months of chemotherapy. Usual care …
Sponsor: NRG Oncology
NCT ID: NCT06958328
Sites in Ohio: - Aultman Health Foundation — Canton, Ohio
- Miami Valley Hospital South — Centerville, Ohio
- University of Cincinnati Cancer Center-UC Medical Center — Cincinnati, Ohio
- Ohio State University Comprehensive Cancer Center — Columbus, Ohio
- Miami Valley Hospital — Dayton, Ohio
Phase 3 Recruiting Network
This phase III trial compares the effect of adding panitumumab to standard chemotherapy (with nanoliposomal Irinotecan, leucovorin, and 5-fluorouracil \[5-FU\] or irinotecan, leucovorin, and 5-FU or nab-paclitaxel and gemcitabine) versus s…
Sponsor: SWOG Cancer Research Network
NCT ID: NCT06998940
Sites in Ohio: - Miami Valley Hospital South — Centerville, Ohio
- University of Cincinnati Cancer Center-UC Medical Center — Cincinnati, Ohio
- Good Samaritan Hospital - Cincinnati — Cincinnati, Ohio
- Bethesda North Hospital — Cincinnati, Ohio
- TriHealth Cancer Institute-Westside — Cincinnati, Ohio
Phase 3 Recruiting Industry
The purpose of this study is to evaluate the efficacy and safety of standard chemotherapy with or without INCB161734 in participants with metastatic pancreatic ductal adenocarcinoma (PDAC).
Sponsor: Incyte Corporation
NCT ID: NCT07522073
Sites in Ohio: - Investigative Site US050 — Cleveland, Ohio
- Investigative Site US020 — Cleveland, Ohio
- Investigative Site US033 — Columbus, Ohio
Phase 3 Recruiting Industry
The purpose of this study is to determine the clinical benefit and characterize the safety profile of tabelecleucel for the treatment of Epstein-Barr virus-associated post-transplant lymphoproliferative disease (EBV+ PTLD) in the setting o…
Sponsor: Pierre Fabre Medicament
NCT ID: NCT03394365
Sites in Ohio: - Cleveland Clinic Foundation (Adults and Pediatrics) — Cleveland, Ohio
- Nationwide Children's Hospital (Pediatrics only) — Columbus, Ohio
- Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (Adults and Pediatrics) — Columbus, Ohio
Phase 2, Phase 3 Recruiting Industry
The primary purpose of this study is to assess the effectiveness of zanzalintinib compared to everolimus in participants with previously treated, unresectable, locally advanced or metastatic neuroendocrine tumors.
Sponsor: Exelixis
NCT ID: NCT06943755
Sites in Ohio: - Exelixis Clinical Site #39 — Cleveland, Ohio
- Exelixis Clinical Site #28 — Columbus, Ohio
Phase 3 Recruiting Industry
This study aims to determine the safety, pharmacokinetics (PK) and recommended Phase 3 dose (RP3D) of RYZ101 in Part 1, and the safety, efficacy, and PK of RYZ101 compared with investigator-selected standard of care (SoC) therapy in Part 2…
Sponsor: RayzeBio, Inc.
NCT ID: NCT05477576
Sites in Ohio: - Research Facility — Cleveland, Ohio
- Research Facility — Columbus, Ohio
Phase 3 Recruiting Industry
The purpose of this study is to evaluate the safety and efficacy of atebimetinib in combination with modified GnP compared with SOC GnP alone.
Sponsor: Immuneering Corporation
NCT ID: NCT07562152
Sites in Ohio: - Taylor Cancer Research Center — Maumee, Ohio
Phase 3 Recruiting Industry
The purpose of this study is to evaluate the safety and efficacy of an investigational RAS(ON) inhibitor administered as monotherapy or in combination with chemotherapy, compared with standard of care (SOC) chemotherapy alone.
Sponsor: Revolution Medicines, Inc.
NCT ID: NCT07491445
Sites in Ohio: - University of Cincinnati Cancer Center — Cincinnati, Ohio
- Taylor Cancer Research Center — Maumee, Ohio
Phase 3 Recruiting Academic/Other
The objectives of this study are to evaluate the glycemic efficacy, safety, and tolerability of ersodetug as add-on to standard of care (SOC) therapy for treatment of hypoglycemia in patients with Tumor Hyperinsulinism (Tumor HI).
Sponsor: Rezolute
NCT ID: NCT06881992
Sites in Ohio: - Investigative Site — Canton, Ohio
Phase 3 Recruiting Industry
The study is designed to assess whether glufosfamide provides additional survival benefit as compared to bolus 5-FU in patients with metastatic pancreatic cancer who have already progressed or failed therapy on a gemcitabine based first li…
Sponsor: Eleison Pharmaceuticals LLC.
NCT ID: NCT01954992
Sites in Ohio: - Gabrail Cancer Center Research — Canton, Ohio
Phase 3 Recruiting Academic/Other
The goal of this clinical trial is to analyze if intraperitoneal drainage is necessary following distal pancreatectomy. This study aims to determine whether the omission of routine intraperitoneal drainage in the setting of reinforced stap…
Sponsor: Case Comprehensive Cancer Center
NCT ID: NCT05720338
Sites in Ohio: - Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center — Cleveland, Ohio
Phase 2 Recruiting NIH
This phase II trial investigates how well the addition of olaparib following completion of surgery and chemotherapy works in treating patients with pancreatic cancer that has been surgically removed (resected) and has a pathogenic mutation…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT04858334
Sites in Ohio: - Miami Valley Hospital South — Centerville, Ohio
- Good Samaritan Hospital - Cincinnati — Cincinnati, Ohio
- Bethesda North Hospital — Cincinnati, Ohio
- TriHealth Cancer Institute-Westside — Cincinnati, Ohio
- TriHealth Cancer Institute-Anderson — Cincinnati, Ohio
Phase 2 Recruiting Network
This phase II trial studies the effect of capecitabine and temozolomide after surgery in treating patients with high-risk well-differentiated pancreatic neuroendocrine tumors. Chemotherapy drugs, such as capecitabine and temozolomide, work…
Sponsor: SWOG Cancer Research Network
NCT ID: NCT05040360
Sites in Ohio: - UH Seidman Cancer Center at UH Avon Health Center — Avon, Ohio
- UHHS-Chagrin Highlands Medical Center — Beachwood, Ohio
- Miami Valley Hospital South — Centerville, Ohio
- University of Cincinnati Cancer Center-UC Medical Center — Cincinnati, Ohio
- Good Samaritan Hospital - Cincinnati — Cincinnati, Ohio
Phase 2 Recruiting Academic/Other
This phase II study evaluates how well pemigatinib works for the treatment of adult patients with pancreatic cancer that has spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced) or has s…
Sponsor: Sameek Roychowdhury
NCT ID: NCT06906562
Sites in Ohio: - Ohio State University-Telemedicine — Cincinnati, Ohio
- Ohio State University-Telemedicine — Cleveland, Ohio
- Ohio State University Comprehensive Cancer Center — Columbus, Ohio
Phase 1, Phase 2 Recruiting Industry
This clinical trial is evaluating a drug called ART0380 in participants with advanced or metastatic solid tumors. The main goals of this study are to: * Find the recommended dose of ART0380 that can be given safely to participants alone an…
Sponsor: Artios Pharma Ltd
NCT ID: NCT04657068
Sites in Ohio: - Oncology Hematology Care Primary — Cincinnati, Ohio
- Taylor Cancer Research Center — Maumee, Ohio
Phase 2 Recruiting Industry
The purpose of this study is to evaluate the efficacy and safety of adjuvant autogene cevumeran plus atezolizumab and modified leucovorin, 5-fluorouracil (5-FU), irinotecan, and oxaliplatin (mFOLFIRINOX) versus mFOLFIRINOX alone in partici…
Sponsor: Genentech, Inc.
NCT ID: NCT05968326
Sites in Ohio: - University of Cincinnati Cancer Institute — Cincinnati, Ohio
Phase 1, Phase 2 Recruiting Network
This phase I/II trial evaluates the highest safe dose, side effects, and possible benefits of tegavivint in treating patients with solid tumors that has come back (recurrent) or does not respond to treatment (refractory). Tegavivint interf…
Sponsor: Children's Oncology Group
NCT ID: NCT04851119
Sites in Ohio: - Cincinnati Children's Hospital Medical Center — Cincinnati, Ohio
Phase 1, Phase 2 Recruiting Industry
Evaluate the safety and tolerability of RMC-6236 in adults with specific RAS mutant advanced solid tumors.
Sponsor: Revolution Medicines, Inc.
NCT ID: NCT05379985
Sites in Ohio: - Christ Hospital Cancer Center — Cincinnati, Ohio
- Taylor Cancer Research Center — Maumee, Ohio
Phase 2 Recruiting Industry
This is a 2-part, Phase 2 study to evaluate the safety, tolerability, dosing, pharmacokinetics (PK), and efficacy of relacorilant in combination with nab-paclitaxel and gemcitabine in chemotherapy-naïve patients with metastatic pancreatic …
Sponsor: Corcept Therapeutics
NCT ID: NCT07259317
Sites in Ohio: - Site 13 — Cincinnati, Ohio
Phase 1, Phase 2 Recruiting Industry
This is a multicenter, open-label, Phase 1/2 study of orally administered VMD-928 monotherapy and in combination with pembrolizumab in adult subjects with advanced solid tumors or lymphoma that have progressed or are non responsive to avai…
Sponsor: VM Oncology, LLC
NCT ID: NCT03556228
Sites in Ohio: - Taylor Cancer Research Center (site 204) — Maumee, Ohio
Phase 1, Phase 2 Recruiting Industry
The goal of this clinical trial is to learn if an investigational drug CP-383 works to treat advanced cancer. It will also learn about the safety of CP-383. The main questions if aims to answer are: * Does CP-383 slow or stop the growth of…
Sponsor: Tasca Therapeutics
NCT ID: NCT07030257
Sites in Ohio: - Cleveland Clinic — Cleveland, Ohio
- Taylor Cancer Research Center — Maumee, Ohio
Phase 1, Phase 2 Recruiting Industry
The goal of this study is to test autologous logic-gated Tmod™ CAR T-cell products in subjects with solid tumors including colorectal cancer (CRC), pancreatic cancer (PANC), non-small cell lung cancer (NSCLC), ovarian cancer (OVCA), mesoth…
Sponsor: A2 Biotherapeutics Inc.
NCT ID: NCT06051695
Sites in Ohio: - The Ohio State University Comprehensive Cancer Center — Columbus, Ohio
Phase 1, Phase 2 Recruiting Industry
Phase I/IIa image-guided, alpha-particle therapy study of \[203Pb\]Pb-PSV359 and \[212Pb\]Pb-PSV359 in patients with solid tumors that are known to be Fibroblast Activation Protein (FAP)-positive.
Sponsor: Perspective Therapeutics
NCT ID: NCT06710756
Sites in Ohio: - Ohio State University — Columbus, Ohio
Phase 1, Phase 2 Recruiting Industry
This is a multicenter, open-label, prospective Phase 1/2a study to assess safety and tolerability, establish dosimetry and to identify an optimal imaging dose (radioactivity) and imaging time window of 64Cu-LNTH-1363S, and to compare its i…
Sponsor: Lantheus Medical Imaging
NCT ID: NCT06298916
Sites in Ohio: - Cincinnati Children's Hospital Medical Center — Cincinnati, Ohio
Phase 1, Phase 2 Recruiting Industry
The purpose of this study is to evaluate the safety and tolerability and overall survival (OS) of E-EDV-D682/GC in combination with gemcitabine and nab-paclitaxel versus gemcitabine and nab-paclitaxel alone in participants with metastatic …
Sponsor: Engeneic Pty Limited
NCT ID: NCT07049055
Sites in Ohio: - Taylor Cancer Center — Maumee, Ohio